Evaluation of the influence of polymorphic variants CYP1A1*2B, CYP1B1*2, CYP3A4*1B, GSTM1*0, and GSTT1*0 in prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 29, Issue 6, 2011, Pages 654-663

  Rodrigues, Iara S ^a   Kuasne, Hellen ^a   Losi Guembarovski, Roberta ^a   Fuganti, Paulo E ^b   Gregório, Émerson P ^b   Kishima, Marina O ^a   Ito, Kazuhiro ^a   De Freitas Rodrigues, Marco A ^a   De Syllos Cólus, Ilce M ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b Hospital do Câncer de Londrina   (Brazil)

Author keywords

Genes of biometabolism; Polymorphisms; Prostate cancer

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; CYTOCHROME P450 3A4; DNA; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE T1;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DNA DETERMINATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; RECURRENCE RISK; RED MEAT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP3A; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS;

EID: 81055148291     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.01.009     Document Type: Article

References (53)

1. Denis L.J., Gospodarowicz M.K., Griffiths K. Câncer de Próstata. UICC Manual de Oncologia Clínica 2006, 584-598. Fundação Oncocentro de São Paulo, São Paulo. 8th ed. R.E. Pollock, J.H. Doroshow, D. Khayat (Eds.).
2. Instituto Nacional do Câncer Síntese de resultados e comentários [texto na Internet] 2008. Disponível em: [acessado 2008 Ago]. http://www.inca.gov.br/estimative.
3. Reszka E., Wasowicz W. Genetic polymorphism of N-acetyltransferase and glutathione S-transferase related to neoplasm of genitourinary system. Neoplasma 2002, 49:209-216.
4. Aktas D., Guney I., Alikasifoglu M., et al. CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm. Gynecol Oncol 2002, 86:124-128.
5. Dong J.T. Prevalent mutations in prostate cancer. J Cell Biochem 2006, 97:433-447.
6. Hayashi S., Watanabe J., Kawajiri K. Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 1991, 110:559-565.
7. Tanaka Y., Sasaki M., Kaneuchi M., et al. Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem Biophys Res Commun 2002, 296:820-826.
8. Aktas D., Hascicek M., Sozen S., et al. CYP1A1 and GSTM1 polymorphic genotypes in patients with prostate cancer in a Turkish population. Cancer Gene Cytogenet 2004, 154:81-85.
9. Chang B.L., Zheng S.L., Isaacs S.D., et al. Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br J Cancer 2003, 89:1524-1529.
10. Hanna I.H., Dawling S., Roodi N., et al. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: Association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Research 2000, 60:3440-3444.
11. Nelson D.R., Kamatasi T., Waxman D.J., et al. The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names, and nomenclature. DNA Cell Biol 1993, 12:1-51.
12. Bangsi D., Zhou J.Y., Sun Y., et al. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men. Urol Oncol 2006, 24:21-27.
13. Amorin L.M.F., Lotsch P.F., Simão T.A., et al. Analysis of CYP1A1 exon 7 polymorphisms by PCR-SSCP in a Brazilian population and description of two novel gene variations. Mutat Res 2004, 547:35-40.
14. Egan K.M., Cai Q., Shu X., et al. Genetic polymorphisms in GSTM1, GSTP1, and GSTT1 and the risk for breast cancer: Results from the Shanghai breast cancer study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2004, 13:197-204.
15. Gattás G.J.F., Kato M., Soares-Vieira J.A., et al. Ethnicity and glutathione S-transferase (GSTM1/GSTT1) polymorphisms in a Brazilian population. Braz J Medi Biol Res 2004, 37:451-458.
16. Grando J.P.S., Kuasne H., Losi-Guembarovski R., et al. Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1, and GSTP1 in bladder cancer. Clin Exp Med 2008, 9:21-28.
17. Engel L.S., Taioli E., Pfeiffer R., et al. Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: A huge review. Am J Epidemiol 2002, 156:95-109.
18. Cotton S.C., Sharp L., Little J., et al. Glutathione S-transferase polymorphisms and colorectal cancer: A huge review. Am J Epidemiol 2000, 151:7-32.
19. Lima M.M., Oliveira M.N.L., Granja F., et al. Lack of Association of GSTT1, GSTM1, GSTO1, GSTP1, and CYP1A1 polymorphisms for susceptibility and outcome in Brazilian prostate cancer patients. Folia Biologica 2008, 54:102-108.
20. Rebbeck T.R. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarks Prev 1997, 6:733-743.
21. Carrano A.V., Natarajan A.T. ICPEMC publication no. 14. Considerations for population monitoring using cytogenetic techniques. Mutat Res 1988, 204:379-406. International Commission for Protection Against Environmental Mutagens and Carcinogens.
22. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extraction DNA from human nucleated cell. Nucleic Acids Res 1988, 16:1215.
23. Drakoulis N., Cascorbi I., Brockmoller J., et al. Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: Exon-7 mutation (4889 A to G), and a T to C mutation in the 3'-flanking region. The J Clinical Investig 1994, 72:240-248.
24. Cavalli S.A., Hirata M.H., Hirara D.C. Detection of MboII polymorphism at the 5' promoter region of CYP3A4. Clin Chem 2001, 47:348-351.
25. Abdel-Rahman S.Z., El-Zein R.A., Anwar W.A., et al. A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies. Cancer Lett 1996, 107:229-233.
26. American Cancer Society. Síntese de resultados e comentários [texto na Internet] 2008.]. Disponível em: [acessado 2008 Out]. http://www.%20cancer.org/docroot/STT/stt_0.asp.
27. Crawford E.D. Epidemiology of Prostate Cancer. Urology 2003, 62:3-12.
28. Carter B.S., Beaty T.H., Steinberg G.D., et al. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1990, 89:3367-3371.
29. Arruda V.R., Grignolli C.E., Gonçalves M.S., et al. Prevalence of homozygosity for the deleted alleles of glutathione S-transferase mu (GSTM1) and theta (GSTT1) among distinct ethnic groups from Brazil: Relevance to environmental carcinogenesis?. Clin Genet 1998, 54:210-214.
30. Sturgis R.C., Wei Q., Spitz M.R. Descriptive epidemiology and risk factors for head and neck cancer. Semin Oncol 2004, 31:726-733.
31. Nebert D.W., Dalton T.P. The role of cytochrome P450 enzymes in endogenous signaling pathways and environmental carcinogenesis. Nature Rev Cancer 2006, 6:947-960.
32. Berndt S.I., Chatterjee N., Huang W.Y., et al. Variant in sex hormone-binding globulin gene and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2007, 16:165-168.
33. Roos P.H., Belik R., Follmann W., et al. Expression of cytochrome P450 enzymes CYP1A1, CYP1B1, CYP2E1, and CYP4B1 in cultured transitional cells from specimens of the human urinary tract and from urinary sediments. Arch Toxicol 2006, 80:45-52.
34. Hefler L.A., Tempfer C.B., Grimm C. Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer 2004, 101:264-269.
35. Nakachi K., Imai K., Hayashi S., et al. Genetic susceptibility to squamous cell carcinoma of the lung in relation to cigarette smoking dose. Cancer Res 1995, 51:5177-5180.
36. Acevedo C., Opazo J.L., Huidobro C. Positive correlation between single or combined genotypes of CYP1A1 and GSTM1 in relation to prostate cancer in Chilean people. Prostate 2003, 57:111-117.
37. Quiñones L.A., Irarrázabal C.E., Rojas C.R., et al. Joint effect among p53 CYP1A1, GSTM1 polymorphism combinations and smoking on prostate cancer risk: An exploratory genotype-environment interaction study. Asian J Androl 2006, 8:349-355.
38. Silig Y., Pinarbasi H., Gunes S., et al. Polymorphisms of CYP1A1, GSTM1, GSTT1, and prostate cancer risk in Turkish population. Cancer Investig 2006, 24:41-45.
39. Figer A., Friedman T., Manguoglu A.E., et al. Analysis of polymorphic patterns in candidate genes in Israeli patients with prostate cancer. Israel Med Assoc J 2003, 5:741-745.
40. Simon D.S., Gregory J.H., Andrew A.R., et al. CYP1B1 expression in human lung. Drug Metab Disp 2001, 29:916-922.
41. Sasaki M., Tanaka Y., Kaneuchi M., et al. CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor α and estrogen receptor β expressions. Cancer Res 2003, 63:3913-3918.
42. Tayeb M.T., Clark C., Haites N.E., et al. CYP3A4 and VDR gene polymorphism and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Cancer 2003, 88:928-932.
43. Sata F., Sapone A., Elizondo G., et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Therapeut 2000, 67:48-56.
44. Sarma A.V., Dunn R.L., Lange L.A., et al. Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: The Flint Men's Health Study. Prostate 2008, 68:296-305.
45. Nogal A., Coelho A., Catarino R., et al. The CYP3A4 *1B polymorphism and prostate cancer susceptibility in a Portuguese population. Cancer Genet Cytogenet 2007, 177:149-152.
46. Cascorbi I. Genetic basis of toxic reactions to drugs and chemicals. Toxicology Lett 2006, 162:16-28.
47. Gajecka M., Rydzanicz M., Jaskula-Sztul R., et al. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1, and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutat Res 2005, 574:29-34.
48. Drummond S.N., Marco L., Noronha J.C.N., et al. GSTM1 polymorphism and oral squamous cell carcinoma. Oral Oncol 2004, 40:52-55.
49. Harries L.W., Stubbins M.J., Forman D., et al. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular, and prostate cancer. Carcinogenesis 1997, 18:641-644.
50. Murata M., Shiraishi T., Fukutome K., et al. Cytochrome P4501A1 and glutathione S-transferase M1 genotypes as risk factors for prostate cancer in Japan. Jpn J Clin Oncol 1998, 28:657-660.
51. Villenueve P.J., Jonhson K.C., Kreiger N., et al. Risk factors for prostate cancer: Results from Canadian National Enhanced Cancer Surveillance System-The Canadian Cancer Registries Epidemiology Research Group. Cancer Causes Control 1999, 10:355-367.
52. D'Amico A.V., Whittington R., Malkowicz S.B., et al. The combination of preoperative prostate specific antigen and postoperative pathologic findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J Urol 1998, 160:2096-2101.
53. Bauer J.J., Srivastava S., Connelly R.R., et al. Significance of familial history of prostate cancer to traditional prognostic variables, genetic biomarkers, and recurrence after radical prostatectomy. Urology 1998, 51:970-976.